ClinicalTrials.gg
RecruitingNCT04700527Updated Oct 5, 2026

The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study

A Phase 1/2 interventional study of Short Chain Fatty Acid and Tapioca Flour in Toxicity and Radiation Toxicity, sponsored by UNC Lineberger Comprehensive Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by UNC Lineberger Comprehensive Cancer Center · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Radiation Injuries with a site in United States — 10 open to participants now, 12 under way, none of them phase 3. Radiation Injuries · United States.

Planned enrollment
12th of 58
122 · median 47
Started
2023
the only one that year
Phase 1/2
7 of 81
1 open now
Primary completion
2027-04
later than 4 of 11 live
Registered
73rd of 81
by date

Among the 81 studies in Radiation Injuries with a site in United States, this one is the 12th largest by planned enrollment of the 58 interventional ones that give a count, is the only one that started in 2023, is one of 7 in phase 1/2, reaches primary completion later than 4 of the 11 other live ones, and was the 73rd registered.

Radiation Injuries

328 studies on the registry are indexed under Radiation Injuries; 96 are open to participants now.

Browse Radiation Injuries studies →

Open to participants now

10 of the 81 studies in Radiation Injuries with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 76 Radiation Injuries studies recruiting now, 52 (68%) set no upper age limit and 14 (18%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Radiation Injuries with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess and compare GI toxicity from RT between subjects who receive therapeutic SCFA and those who receive placebo, in hopes of identifying a safe, low-cost therapeutic to reduce GI toxicity from therapeutic or environmental radiation.

Read the detailed description

Radiation therapy is a critical modality for treatment of urologic, gynecologic and gastrointestinal malignancies among others. Though advances in treatment techniques have reduced treatment-associated morbidity and mortality, normal tissue toxicity still limits dose escalation and treatment tolerance. Over 50% of patients receiving abdominal or pelvic radiation therapy (RT) develop clinically meaningful toxicity. Pharmacologic strategies to reduce normal tissue damage represent a tremendous unmet need in RT. Investigators propose a novel application of short chain fatty acids (SCFA) as a therapeutic to reduce incidence and severity of gastrointestinal (GI) toxicity from RT. Short chain fatty acids (SCFA) are fatty acids with fewer than six carbon atoms ingested or formed during bacterial fermentation of partially- and non-digestible polysaccharides carbohydrates. Patients who are enrolled will be randomized to receive SCFA supplements or a placebo, and will start taking it everyday one week prior to starting RT through 1 week after completing RT. Patients will keep a log of daily administration during the entire time while taking the study drug, and will complete patient reported outcomes (PROs) involving toxicities starting at baseline through 3 months post RT. The patient's treating physician will also complete an assessment of the patients toxicities starting at the baseline through follow up visits up to 5 years post RT, which will be used to compare to the PROs.

03

Conditions studied

  • Toxicity
  • Radiation Toxicity

Keywords

  • GI cancer
  • Urinary cancer
  • Gynecological Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written obtained to participate in the study and HIPAA authorization for release of personal health information. Consent for the use of any residual material from and/or surgical resection (archival tissue) and serial blood draws will be required for enrollment.
  • ≥ 18 years of age on day of signing informed consent.
  • performance score ≤ 2
  • Subjects with histological or cytological evidence/confirmation of GI, urologic or gynecologic (including sarcoma) that will be treated with minimum dose of 40Gy (equivalent dose in 2Gy per fraction or EQD2) via 3D conformal fields or IMRT to abdomen or pelvis (multimodality treatment with surgery, systemic anti cancer therapy is permissible)
  • Subjects may have had prior chemotherapy or surgery.
  • Subjects deemed healthy for study inclusion by the treating physician based on the laboratory values at screening and general health status.
  • Prior cancer treatment must be completed at least 14 days prior to registration and the subject must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to ≤ Grade 1 or baseline.
  • Females of must have a negative urine pregnancy test within 14 days prior to simulation. NOTE: Females are considered of childbearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are naturally for at least 12 consecutive months. Documentation of postmenopausal status must be provided.
  • Females of childbearing potential must be willing to abstain from heterosexual activity or to use 2 forms of effective methods of from the time of informed consent until 14 or 28 days after treatment discontinuation. The two contraception methods can be comprised of two barrier methods, or a barrier method plus a hormonal method or an intrauterine device that meets \< 1% failure rate for protection from pregnancy in the product label.
  • Male subjects with female partners of childbearing potential must have had a prior vasectomy or agree to use an adequate method of contraception (i.e., double barrier method: condom plus spermicidal agent) starting with the first dose of study therapy through 14-28 days after the last dose of study therapy.
  • Subjects is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).
  • Prior abdominopelvic RT to a region with anticipated direct overlap with the present planned course of RT.
  • History of inflammatory bowel disease or GI motility disorder
  • Grade 2 or higher diarrhea at baseline unless deemed by the investigator to be caused by laxatives prescribed for symptomatic partial obstruction
  • Concurrent use of histone deacetylase inhibitors (vorinostat)
  • Baseline hypernatremia defined as serum sodium concentration >145 mEg/L
  • \< 50 mL/min
  • Congestive heart failure
  • On a salt restricted diet for medical indications
  • Severe nut allergy
  • Active central nervous system (CNS)
  • Subject must have completed treatment with any drug other than the drugs in this study and subjects may not be on another clinical trial by no less than 14 days prior to registration. Subjects participating in interventional trials that does not include an investigational agent or any other drug are allowed at the discretion of the principal investigator.
  • Subject is receiving prohibited medications or treatments as listed in section 5.6 of the protocol that cannot be discontinued/replaced by an alternative therapy.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
122 participants (estimated)

Study arms

  • Active comparator
    Short Chain Fatty Acid (SCFA)

    4-6 grams of powder mixed with food and taken everyday starting 1 week prior-1 week post Radiation Therapy.

    Drug: Short Chain Fatty Acid

  • Placebo comparator
    Placebo (Tapioca)

    5 grams taken everyday starting 1 week prior-1 week post Radiation Therapy.

    Drug: Tapioca Flour

Interventions

  • DrugShort Chain Fatty Acid

    Participants will take the supplement as prescribed to determine if it can help with GI toxicity

    Also known as: Sodium butyrate and sodium propionate

  • DrugTapioca Flour

    Participants taking this will be used as a control group compared to those receiving the SCFA supplement

06

What researchers measure

Primary outcomes

  1. The rate and severity of patient reported and physician determined toxicities between subjects who receive therapeutic SCFA and those who receive placebo.

    GI toxicities (PRO-CTCAE v5 for patients and CTCAE v5 for physicians) will be recorded and compared between the 2 groups to identify any differences.

    Time frame: baseline-3 months

Secondary outcomes

  1. Physician determined acute toxicity profile using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, version 5.0) for both subjects who receive therapeutic SCFA versus those who receive placebo.

    Physicians will complete toxicity assessments using the CTCAE v5 at each visit with the patient up until 5 years post RT

    Time frame: baseline- up to 5 years post RT

  2. Subject reported acute toxicity profile as ascertained by patient-reported outcomes version of the CTCAE (PRO-CTCAE) for both subjects who receive therapeutic SCFA versus those who receive placebo.

    Patients will complete PRO-CTCAE at each visit starting at baseline through 3 months after completing the study drug.

    Time frame: baseline- 3 months

07

Study locations

1 of 1 sites recruiting
  • Flora Danquah
    Chapel Hill, North Carolina 27599, United States
    Recruiting
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2023 (actual). Primary completion is estimated for Apr 2027, 40 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2020
First posted
Jan 8, 2021
StartActual
Dec 15, 2023
Primary completionEst.
Apr 21, 2027
CompletionEst.
May 2031
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and data sharing statement
1 update, last Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Minor edits only
    + 2 other changes: verification date and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04700527
Responsible party
Sponsor
First posted
Jan 8, 2021
Start date
Dec 15, 2023
Primary completion
Apr 21, 2027 (estimated)
Completion
May 2031 (estimated)
Last update
Oct 5, 2026

Study contacts

Flora Danquah
Contact
flora_danquah@med.unc.edu
9849748441
Shivani Sud, MD
principal investigator · UNC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion